U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

CCNE1 Gene Amplification

MedGen UID:
267934
•Concept ID:
C1511414
•
Cell or Molecular Dysfunction
Synonyms: CCNE Gene Amplification; CCNE1 Amplification; CCNE1 Copy Number Gain; Cyclin E1 Gene Amplification

Definition

A molecular genetic abnormality indicating the presence of multiple copies of the CCNE1 gene. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVCCNE1 Gene Amplification

Professional guidelines

PubMed

Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.
Kwon HJ, Park Y, Nam SK, Kang E, Kim KK, Jeong I, Kwak Y, Yoon J, Kim TY, Lee KW, Oh DY, Im SA, Kong SH, Park DJ, Lee HJ, Kim HH, Yang HK, Lee HS
Cancer Med 2023 May;12(9):10371-10384. Epub 2023 Mar 14 doi: 10.1002/cam4.5769. PMID: 36916290Free PMC Article
Molecular profiling of gynecologic cancers for treatment and management of disease - demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants.
Nie Q, Omerza G, Chandok H, Prego M, Hsiao MC, Meyers B, Hesse A, Uvalic J, Soucy M, Bergeron D, Peracchio M, Burns S, Kelly K, Rowe S, Rueter J, Reddi HV
Cancer Genet 2020 Apr;242:25-34. Epub 2020 Jan 14 doi: 10.1016/j.cancergen.2019.11.008. PMID: 31992506
Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.
Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M; Australian Ovarian Cancer Study Group, Gorringe KL, Smyth GK, Bowtell DD
PLoS One 2010 Nov 12;5(11):e15498. doi: 10.1371/journal.pone.0015498. PMID: 21103391Free PMC Article

Recent clinical studies

Etiology

Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications.
Weigelt B, Marra A, Selenica P, Rios-Doria E, Momeni-Boroujeni A, Berger MF, Arora K, Nemirovsky D, Iasonos A, Chakravarty D, Abu-Rustum NR, Da Cruz Paula A, Dessources K, Ellenson LH, Liu YL, Aghajanian C, Brown CL
Cancer Discov 2023 Nov 1;13(11):2356-2369. doi: 10.1158/2159-8290.CD-23-0546. PMID: 37651310Free PMC Article
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S
Sci Rep 2022 May 24;12(1):8701. doi: 10.1038/s41598-022-12669-5. PMID: 35610322Free PMC Article
High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
Aziz D, Lee C, Chin V, Fernandez KJ, Phan Z; kConFab Investigators; AOCS Study Group, Waring P, Caldon CE
J Pathol Clin Res 2022 Jul;8(4):355-370. Epub 2022 Apr 6 doi: 10.1002/cjp2.269. PMID: 35384378Free PMC Article
Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J; Australian Ovarian Cancer Study Group, Davis S, D'Andrea AD, Simpson K, Hahn WC, Bowtell DD
Proc Natl Acad Sci U S A 2013 Nov 26;110(48):19489-94. Epub 2013 Nov 11 doi: 10.1073/pnas.1314302110. PMID: 24218601Free PMC Article

Diagnosis

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S
Sci Rep 2022 May 24;12(1):8701. doi: 10.1038/s41598-022-12669-5. PMID: 35610322Free PMC Article
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.
Yang L, Fang D, Chen H, Lu Y, Dong Z, Ding HF, Jing Q, Su SB, Huang S
Oncotarget 2015 Aug 28;6(25):20801-12. doi: 10.18632/oncotarget.4600. PMID: 26204491Free PMC Article
Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J; Australian Ovarian Cancer Study Group, Davis S, D'Andrea AD, Simpson K, Hahn WC, Bowtell DD
Proc Natl Acad Sci U S A 2013 Nov 26;110(48):19489-94. Epub 2013 Nov 11 doi: 10.1073/pnas.1314302110. PMID: 24218601Free PMC Article
Functional characterization of the 19q12 amplicon in grade III breast cancers.
Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS
Breast Cancer Res 2012 Mar 20;14(2):R53. doi: 10.1186/bcr3154. PMID: 22433433Free PMC Article

Therapy

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S
Sci Rep 2022 May 24;12(1):8701. doi: 10.1038/s41598-022-12669-5. PMID: 35610322Free PMC Article
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD
Br J Cancer 2016 Jul 26;115(3):303-11. Epub 2016 Jun 28 doi: 10.1038/bjc.2016.198. PMID: 27351214Free PMC Article
Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J; Australian Ovarian Cancer Study Group, Davis S, D'Andrea AD, Simpson K, Hahn WC, Bowtell DD
Proc Natl Acad Sci U S A 2013 Nov 26;110(48):19489-94. Epub 2013 Nov 11 doi: 10.1073/pnas.1314302110. PMID: 24218601Free PMC Article

Prognosis

High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
Aziz D, Lee C, Chin V, Fernandez KJ, Phan Z; kConFab Investigators; AOCS Study Group, Waring P, Caldon CE
J Pathol Clin Res 2022 Jul;8(4):355-370. Epub 2022 Apr 6 doi: 10.1002/cjp2.269. PMID: 35384378Free PMC Article
Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.
Kanska J, Zakhour M, Taylor-Harding B, Karlan BY, Wiedemeyer WR
Gynecol Oncol 2016 Oct;143(1):152-158. Epub 2016 Jul 25 doi: 10.1016/j.ygyno.2016.07.111. PMID: 27461360
Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K
Cancer 2010 Jun 1;116(11):2621-34. doi: 10.1002/cncr.24987. PMID: 20336784

Clinical prediction guides

Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications.
Weigelt B, Marra A, Selenica P, Rios-Doria E, Momeni-Boroujeni A, Berger MF, Arora K, Nemirovsky D, Iasonos A, Chakravarty D, Abu-Rustum NR, Da Cruz Paula A, Dessources K, Ellenson LH, Liu YL, Aghajanian C, Brown CL
Cancer Discov 2023 Nov 1;13(11):2356-2369. doi: 10.1158/2159-8290.CD-23-0546. PMID: 37651310Free PMC Article
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S
Sci Rep 2022 May 24;12(1):8701. doi: 10.1038/s41598-022-12669-5. PMID: 35610322Free PMC Article
Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J; Australian Ovarian Cancer Study Group, Davis S, D'Andrea AD, Simpson K, Hahn WC, Bowtell DD
Proc Natl Acad Sci U S A 2013 Nov 26;110(48):19489-94. Epub 2013 Nov 11 doi: 10.1073/pnas.1314302110. PMID: 24218601Free PMC Article
Functional characterization of the 19q12 amplicon in grade III breast cancers.
Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS
Breast Cancer Res 2012 Mar 20;14(2):R53. doi: 10.1186/bcr3154. PMID: 22433433Free PMC Article
Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K
Cancer 2010 Jun 1;116(11):2621-34. doi: 10.1002/cncr.24987. PMID: 20336784

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...